# A Phase I Study of JS108 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct04601285/  
OnCo record `nct04601285` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests TROP-2-directed treatment; the registry reports that it is terminated.

## Summary

The registry lists NCT04601285 as terminated, last updated 2023-07-06. Enrolment is 25 actual participants. Interventions: JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection). Primary measures include First Cycle Dose Limiting Toxicities (DLTs) In Order to Determine the Maximum Tolerated Dose(MTD); Number of participants with adverse events (AEs). The registry reason for stopping is: Sponsor has adjusted study development plan and terminated this clinical study. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-10-06
- Registry id: NCT04601285
- Phase: 1
- Setting: A Phase I, Open-label, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Recombinant Humanized Anti-Trop2 mAb-Tub196 Conjugate in Patients With Advanced Solid Tumors.
- Sponsor: Shanghai Junshi Bioscience Co., Ltd.
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT04601285: https://clinicaltrials.gov/study/NCT04601285

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [JS108](https://onco.cc/drugs/js108/)

---
JSON: https://onco.cc/api/v1/entities/nct04601285.json